Courage Atekha, MD
Nephrology · Statesboro, GANPI 1124119219
Payments from drug & device makers
Across 493 payments — averaging $630.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$127K
- GSK$118K
- Merck$37K
- AstraZeneca$20K
- CSL Behring$4K
- OPKO Pharmaceuticals, LLC$885
- plus $4K from 20 others
Across 6 payments — averaging $7680.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$46K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 159 | $127,454 |
| GSK | 19 | $117,659 |
| Merck | 11 | $36,663 |
| AstraZeneca | 65 | $19,921 |
| CSL Behring | 24 | $4,270 |
| OPKO Pharmaceuticals, LLC | 48 | $885 |
| Amgen(2 entities) | 31 | $733 |
| Travere Therapeutics, Inc. | 27 | $572 |
| Ardelyx, Inc. | 19 | $545 |
| Calliditas Therapeutics US Inc. | 16 | $470 |
| Vifor Pharma, Inc. | 17 | $376 |
| Otsuka America Pharmaceutical, Inc. | 14 | $331 |
| Bayer | 14 | $268 |
| Fresenius USA Marketing, Inc. | 9 | $181 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $106 |
| Novo Nordisk | 4 | $84 |
| Boehringer Ingelheim | 4 | $71 |
| Mallinckrodt Hospital Products Inc. | 3 | $47 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Novartis | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$310,797 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Statesboro
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
- Laura MulloyAugusta$891K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.